{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/bronchiectasis/prescribing-information/clarithromycin/","result":{"pageContext":{"chapter":{"id":"26b521e3-9c5e-5a7c-956b-7f3f39f2e58c","slug":"clarithromycin","fullItemName":"Clarithromycin","depth":2,"htmlHeader":"<!-- begin field b9199f46-6b74-4c25-b9ec-1f4c11d504f7 --><h2>Clarithromycin</h2><!-- end field b9199f46-6b74-4c25-b9ec-1f4c11d504f7 -->","summary":"","htmlStringContent":"<!-- begin item a2f27a8b-7bdb-41ec-9eb0-63bc10f66f1c --><!-- end item a2f27a8b-7bdb-41ec-9eb0-63bc10f66f1c -->","topic":{"id":"96a8622b-46f5-55fa-b729-6748e3d98c98","topicId":"26fab339-e333-44ec-a481-de87a29052f3","topicName":"Bronchiectasis","slug":"bronchiectasis","lastRevised":"Last revised in January 2021","chapters":[{"id":"43d88c30-f768-5e1c-a6ea-5596c5577fb5","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"ac4fde9a-5fd3-5ed9-9201-f714bda470bb","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"0b34af83-d49a-5145-8589-e8748b8646c0","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"04eeb1ae-4fc3-5418-83a2-b62587d8bdda","slug":"changes","fullItemName":"Changes"},{"id":"dbd8ad5a-871c-59b8-9729-444e11ac9df1","slug":"update","fullItemName":"Update"}]},{"id":"b89644c6-805f-50b4-991d-36bb2b0fbf67","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d38de329-73b8-5fed-83ef-f836b765cd3f","slug":"goals","fullItemName":"Goals"},{"id":"3c116665-5586-5551-909c-0efc1ef0be62","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"60e13bc0-e351-5c39-b8ff-9a8d4514bf16","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"2ee37cc0-9ff4-5bbd-ab3f-0a30cb904bb5","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"d155aa4f-7dfe-575d-a7dd-a87774f4cbad","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"07c3e24b-c950-516e-9070-5441a07b3791","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"5146c866-f0a7-54a6-a5ac-8aff4b385cc6","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"e2107a7e-b7c3-5ba9-94e4-6217ea79a3f2","slug":"definition","fullItemName":"Definition"},{"id":"39df7c47-de08-57ae-aa40-89a7d4d7b031","slug":"causes","fullItemName":"Causes"},{"id":"ac4d346e-97d4-5d84-a704-fbdcf56be7f4","slug":"prevalence","fullItemName":"Prevalence"},{"id":"e07a8b0b-866c-5789-85ef-020a5b19b620","slug":"prognosis-complications","fullItemName":"Prognosis and complications"}]},{"id":"ef5c5e7b-3cf4-5939-85e0-b61cae41f945","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"ce267b5b-70dd-52bd-ad83-6123bd42fa0d","slug":"diagnosis","fullItemName":"Diagnosis"},{"id":"c605c0b9-0519-50e1-abd8-2dc47de7278a","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"},{"id":"23a1627d-30f7-5ba4-95f8-060faf797f51","slug":"suspected-infective-exacerbation-diagnosis","fullItemName":"Suspected infective exacerbation diagnosis"}]},{"id":"5a5846fa-c8b4-5cd4-b2d3-770c3dc00ba2","fullItemName":"Management","slug":"management","subChapters":[{"id":"0180d43c-dd8d-5a87-915c-629542f782fe","slug":"suspected-bronchiectasis","fullItemName":"Scenario: Suspected bronchiectasis"},{"id":"290c51ae-6521-5c03-b12e-117e40c88883","slug":"infective-exacerbation","fullItemName":"Scenario: Infective exacerbation"},{"id":"1e90ec28-8eea-5ab7-ac76-2df1ace279de","slug":"covid-19","fullItemName":"Scenario: COVID-19"}]},{"id":"ba1a593e-f80b-5c5f-be50-5979b491bc70","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"6db0266e-4d15-5eec-b2c0-ed20f472eeb5","slug":"azithromycin","fullItemName":"Azithromycin"},{"id":"a98b5813-5589-5247-9c65-e9ae534d88c2","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"04c99c8f-7a1d-55f0-85a2-6d0e1bc3e4e3","slug":"ciprofloxacin","fullItemName":"Ciprofloxacin"},{"id":"26b521e3-9c5e-5a7c-956b-7f3f39f2e58c","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"6cd6079a-be84-5279-9d10-e3bf4653c049","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"8ed4a900-3e69-51c0-8cd5-c2b0bee9bfe2","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"5217d027-064d-5543-93b0-7e8bb1a1c0fc","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"cf1fbf18-e60a-54f7-bbc4-2a30ab37f565","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"8e888abe-cb05-5343-b6e3-547dea7312cc","slug":"beta-2-agonists","fullItemName":"Beta-2 agonists"}]},{"id":"118b4e08-e6ae-510a-b2f5-51b109ef3395","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"ecf8de37-d8f0-5ced-af38-9be20fa73de9","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"1c227675-02ea-5c9e-a927-e385987adf53","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f74bbe64-1998-528f-b811-df2a14219de7","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"2a925d45-6865-5cd5-9624-23da53ee221a","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"a6ff3076-9be6-55b4-b373-f40cb3045f2c","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"67608f46-5eba-58f9-86e3-0e0e3f57d921","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"3fae7f8d-20fb-5fe6-af57-64882afceb3a","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"ba1a593e-f80b-5c5f-be50-5979b491bc70","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"e7398a68-c258-511f-b4c8-87039240d3ef","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field b97b1e5d-0977-4c22-9283-540c00f67281 --><h3>What contraindications and cautions are associated with clarithromycin?</h3><!-- end field b97b1e5d-0977-4c22-9283-540c00f67281 -->","summary":"","htmlStringContent":"<!-- begin item f475aba7-25d3-42eb-a56b-f03a4809b958 --><!-- begin field 1bcb4962-68f8-4101-a0b9-2912e835f81f --><ul><li><strong>Do not prescribe clarithromycin to people:</strong><ul><li>With severe hepatic impairment in combination with renal impairment.</li><li>Taking drugs that prolong the QT interval (for example haloperidol, sotalol, terfenadine, and pimozide) — macrolides can also prolong the QT interval, which is a risk factor for torsades de pointes.</li><li>With hypokalaemia — due to the risk of prolongation of the QT interval.</li><li>With a history of QT prolongation or ventricular cardiac arrhythmia, including torsades de pointes.</li></ul></li><li><strong>Prescribe clarithromycin with caution to people with:</strong><ul><li>Coronary artery disease, severe cardiac insufficiency, or bradycardia (less than 50 beats per minute) — increased risk of QT prolongation.</li><li>A predisposition to QT interval prolongation.</li><li>Electrolyte disturbances, such as hypomagnesaemia. </li><li>Hepatic impairment (or people concomitantly receiving potentially hepatotoxic drugs) — clarithromycin is mainly excreted by the liver.</li><li>Renal impairment — use half the normal dose in severe renal impairment (eGFR less than 30 mL/minute) for a maximum duration of 14 days. Avoid Klaricid XL (clarithromycin prolonged release once daily tablets) as the dose cannot be reduced.</li><li>Myasthenia gravis — macrolides may aggravate weakness symptoms.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">ABPI, 2020e</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field 1bcb4962-68f8-4101-a0b9-2912e835f81f --><!-- end item f475aba7-25d3-42eb-a56b-f03a4809b958 -->","subChapters":[]},{"id":"a09dd1a7-f2ec-563d-8c18-9563f073ab4d","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field bd50a836-b0b4-4822-8e75-c3149f0e0fbb --><h3>What are the adverse effects of clarithromycin?</h3><!-- end field bd50a836-b0b4-4822-8e75-c3149f0e0fbb -->","summary":"","htmlStringContent":"<!-- begin item 3b8bc084-40ca-4cbb-99c8-fd92e89946c3 --><!-- begin field c52373c1-8403-4446-99dd-53555d65786d --><ul><li><strong>Gastrointestinal</strong> — diarrhoea, vomiting, dyspepsia, nausea, abdominal pain (common).<ul><li><strong>Rarely: </strong>pancreatitis, pseudomembranous colitis. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li><strong>Nervous system</strong> — headache, dysgeusia (common), dizziness, somnolence, tremor (uncommon).<ul><li><strong>Rarely:</strong> convulsions, paraesthesia.</li></ul></li><li><strong>Psychiatric</strong> — insomnia (common), anxiety, nervousness (uncommon).<ul><li><strong>Rarely or very rarely: </strong>psychotic disorders, depression, mania, hallucination.</li></ul></li><li><strong>Skin</strong> — rash, hyperhidrosis (common), pruritus, urticaria (uncommon).<ul><li><strong>Rarely, or very rarely:</strong> drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens–Johnson syndrome, toxic epidermal necrolysis.</li></ul></li><li><strong>Other adverse effects reported rarely, or very rarely, include:</strong> <ul><li>Anaphylaxis.</li><li>Arrhythmias, QT interval prolongation.</li><li>Hearing impairment.</li><li>Hepatic failure, jaundice.</li><li>Pancreatitis. </li><li>Renal failure.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">ABPI, 2020e</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">Joint Formulary Committee, 2020</a>]</p><!-- end field c52373c1-8403-4446-99dd-53555d65786d --><!-- end item 3b8bc084-40ca-4cbb-99c8-fd92e89946c3 -->","subChapters":[]},{"id":"2cb87889-c294-5e86-a1c5-22c3496f97dc","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field 6ac32f31-e78d-4f8c-a2b8-7bbffee86182 --><h3>What drug interactions are important with clarithromycin?</h3><!-- end field 6ac32f31-e78d-4f8c-a2b8-7bbffee86182 -->","summary":"","htmlStringContent":"<!-- begin item 6e02a8e5-e279-4506-b4cc-d52a701bfb10 --><!-- begin field 558c63eb-c8fc-49c9-99c7-544fc04d0010 --><ul><li><strong>Calcium channel blockers (CCBs) </strong>— there is an increased risk of hypotension if CCBs (such as verapamil, amlodipine, and diltiazem) are taken concurrently with clarithromycin, as they are metabolised by CYP3A4. This may also lead to increased levels of clarithromycin.</li><li><strong><strong><strong>Carbamazepine</strong> — clarithromycin significantly increases carbamazepine levels.</strong></strong><ul style=\"font-weight: 400;\"><li>Reduce the dose of carbamazepine by 30–50% during treatment with clarithromycin and monitor within 3–5 days. </li><li>Advise the person to report symptoms of carbamazepine toxicity (such as dizziness, diplopia, ataxia, or confusion).</li></ul></li><li><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'segoe ui', Roboto, Oxygen, Ubuntu, Cantarell, 'open sans', 'helvetica neue', sans-serif;\">Ciclosporin </strong>— erythromycin can affect clearance of ciclosporin. If co-administration of these drugs is necessary, ciclosporin levels should be monitored and the dose adjusted accordingly.</li><li><strong>Cisapride </strong>— levels may be increased. Avoid concurrent use. </li><li><strong>Colchicine</strong> — clarithromycin moderately increases the levels of colchicine. The manufacturer advises that concurrent use is contraindicated.</li><li><strong>CYP3A enzyme inducers </strong>(rifampicin, carbamazepine, phenobarbital) — these may induce the metabolism of clarithromycin, resulting in sub-therapeutic levels.<ul><li>It may be necessary to monitor the levels of these drugs, as CYP3A is inhibited by clarithromycin leading to higher plasma levels of the inducer.</li></ul></li><li><strong>Digoxin</strong> — clarithromycin significantly increases digoxin levels. Monitor for signs of adverse effects, measure digoxin levels, and reduce the digoxin dose if required.</li><li><strong>Edoxaban </strong>— levels may be increased by clarithromycin. Dose adjustment of edoxaban may be required.</li><li><strong>Ergot alkaloids</strong> — concomitant administration is contraindicated, due to the risk of acute ergot toxicity.</li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are not required during or after courses of clarithromycin.<ul><li>However, women should be advised that if diarrhoea, vomiting, or breakthrough bleeding occur there is a possibility of contraceptive failure. For further information, see the sections on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li><li><strong>Oral hypoglycaemic drugs (sulfonylureas) and insulin </strong>— the concomitant use of clarithromycin and oral hypoglycaemic drugs and/or insulin can result in significant hypoglycaemia. Monitor glucose levels.</li><li><strong>Statins (atorvastatin, simvastatin) </strong>— these are extensively metabolised by CYP3A4. Concomitant administration with clarithromycin increases the plasma levels and the risk of myopathy.<ul><li>Simvastatin — do not prescribe clarithromycin to a person taking simvastatin. If treatment with clarithromycin cannot be avoided, stop treatment with simvastatin temporarily.</li><li>Atorvastatin — avoid concurrent use with clarithromycin. If concurrent use cannot be avoided, prescribe the lowest dose of atorvastatin.</li></ul></li><li><strong>Typhoid vaccine </strong>— antibacterials might reduce the immune response. The World Health Organization (WHO) recommends that the antibacterial is stopped from 3 days before to 3 days after receiving live oral typhoid vaccine.</li><li><strong>Warfarin </strong>— clarithromycin increases the anticoagulant effect of warfarin. Monitor the international normalized ratio (INR), and adjust the warfarin dose accordingly.</li><li><strong>Drugs that prolong the QT interval </strong>(such as amiodarone, sotalol, domperidone) — all macrolides can prolong the QT interval, and concomitant use of drugs that prolong the QT interval is contraindicated.</li><li><strong>Drugs that cause hypokalaemia</strong> (such as diuretics, corticosteroids, short-acting beta-2 agonists). Monitor potassium levels closely.</li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/bronchiectasis/references/\">Preston, 2020</a>]</p><!-- end field 558c63eb-c8fc-49c9-99c7-544fc04d0010 --><!-- end item 6e02a8e5-e279-4506-b4cc-d52a701bfb10 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}